Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (536) 536
Publication (90) 90
Book Chapter (7) 7
Conference Proceeding (3) 3
Book Review (1) 1
Data Set (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pd1 (252) 252
index medicus (240) 240
immunotherapy (232) 232
oncology (215) 215
humans (185) 185
cancer (136) 136
anti-pd1 (133) 133
immunology (111) 111
melanoma (108) 108
nivolumab (105) 105
female (78) 78
pembrolizumab (76) 76
chemotherapy (73) 73
ipilimumab (72) 72
pd-l1 (72) 72
animals (64) 64
expression (63) 63
pdl1 (62) 62
lymphocytes (58) 58
t cells (56) 56
care and treatment (55) 55
male (53) 53
middle aged (52) 52
programmed cell death 1 receptor - antagonists & inhibitors (52) 52
metastasis (51) 51
metastatic melanoma (49) 49
tumors (49) 49
open-label (48) 48
survival (47) 47
aged (46) 46
pd-1 (46) 46
safety (46) 46
research (45) 45
programmed cell death 1 receptor - immunology (44) 44
antineoplastic agents - therapeutic use (43) 43
apoptosis (43) 43
immune checkpoint (43) 43
t-cells (43) 43
immune checkpoint inhibitors (42) 42
adult (40) 40
ctla4 (40) 40
lung cancer (40) 40
prognosis (39) 39
antibodies, monoclonal - therapeutic use (38) 38
immunotherapy - methods (38) 38
blockade (35) 35
neoplasms. tumors. oncology. including cancer and carcinogens (35) 35
anti-ctla4 (34) 34
antibodies (34) 34
review (34) 34
lymphocytes t (33) 33
therapy (33) 33
health aspects (32) 32
biomarkers (31) 31
mice (31) 31
medicine, research & experimental (30) 30
patients (30) 30
analysis (29) 29
article (28) 28
clinical trials (28) 28
gene expression (28) 28
cell death (27) 27
ctla-4 (27) 27
ligands (27) 27
pd-1 blockade (27) 27
antigens (26) 26
drug therapy (26) 26
medicine & public health (26) 26
neoplasms - immunology (26) 26
melanoma - drug therapy (25) 25
cancer therapies (24) 24
original research (24) 24
pharmacology & pharmacy (24) 24
tumor-infiltrating lymphocytes (24) 24
cytotoxicity (23) 23
treatment outcome (23) 23
usage (23) 23
b7-h1 antigen - immunology (22) 22
biochemistry & molecular biology (22) 22
lymphomas (22) 22
medical research (22) 22
b7-h1 antigen - antagonists & inhibitors (21) 21
cell biology (21) 21
cell lung-cancer (21) 21
dermatology (21) 21
genetic aspects (21) 21
lung cancer, non-small cell (21) 21
multicenter (21) 21
neoplasms - therapy (21) 21
tumor microenvironment (21) 21
aged, 80 and over (20) 20
antibody (20) 20
antineoplastic agents - adverse effects (20) 20
hematology (20) 20
lymphoma (20) 20
mutation (20) 20
antibodies, monoclonal, humanized - therapeutic use (19) 19
biotechnology & applied microbiology (19) 19
cancer immunotherapy (19) 19
checkpoint blockade (19) 19
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (495) 495
French (22) 22
German (6) 6
Japanese (4) 4
Spanish (4) 4
Chinese (2) 2
Hungarian (2) 2
Korean (2) 2
Czech (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types
by Paré, L and Pascual, T and Seguí, E and Teixidó, C and Gonzalez-Cao, M and Galván, P and Rodríguez, A and González, B and Cuatrecasas, M and Pineda, E and Torné, A and Crespo, G and Martin-Algarra, S and Pérez-Ruiz, E and Reig, Ò and Viladot, M and Font, C and Adamo, B and Vidal, M and Gaba, L and Muñoz, M and Victoria, I and Ruiz, G and Viñolas, N and Mellado, B and Maurel, J and Garcia-Corbacho, J and Molina-Vila, M Á and Juan, M and Llovet, J M and Reguart, N and Arance, A and Prat, A
Annals of Oncology, ISSN 0923-7534, 10/2018, Volume 29, Issue 10, pp. 2121 - 2128
Abstract Background We hypothesized that the abundance of PD1 mRNA in tumor samples might explain the differences in overall response rates (ORR) observed... 
Anti-PD1 | Solid tumors | Gene expression | PD1 | Immunotherapy | IMMUNE | ONCOLOGY | immunotherapy | anti-PD1 | TUMOR MUTATIONAL BURDEN | EXPRESSION | gene expression | solid tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis
by Passiglia, Francesco and Bronte, Giuseppe and Bazan, Viviana and Natoli, Clara and Rizzo, Sergio and Galvano, Antonio and Listì, Angela and Cicero, Giuseppe and Rolfo, Christian and Santini, Daniele and Russo, Antonio
Oncotarget, ISSN 1949-2553, 04/2016, Volume 7, Issue 15, pp. 19738 - 19747
Clinical trials of immune checkpoints modulators, including both programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) inhibitors, have... 
PD-L1 | NSCLC | Anti-PD1/PD-L1 MoAbs | Immunotherapy | Predictive biomarker | Immunohistochemistry | Outcome Assessment (Health Care) - methods | Lung Neoplasms - drug therapy | Prognosis | Humans | Lung Neoplasms - metabolism | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Agents | Antibodies, Monoclonal - therapeutic use | B7-H1 Antigen - immunology | Outcome Assessment (Health Care) - statistics & numerical data | B7-H1 Antigen - biosynthesis | Carcinoma, Non-Small-Cell Lung - drug therapy | Odds Ratio | Biomarkers, Tumor - biosynthesis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text The use of immunotherapy in the treatment of melanoma Ahmed Tarhini; Timothy Burns; Rahul Parikh; Guarvel Goel; Annie im
by Achkar, Tala and Tarhini, Ahmad A
Journal of Hematology and Oncology, 04/2017, Volume 10, Issue 1
Anti-PD1 | Anti-CTLA4 | Immunotherapy | Melanoma
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
by Wöckel, Achim and Lux, Michael P and Janni, Wolfgang and Hartkopf, Andreas D and Nabieva, Naiba and Taran, Florin-Andrei and Overkamp, Friedrich and Hadji, Peyman and Tesch, Hans and Ettl, Johannes and Lüftner, Diana and Müller, Volkmar and Welslau, Manfred and Belleville, Erik and Brucker, Sara Y and Schütz, Florian and Fasching, Peter A and Fehm, Tanja N and Schneeweiss, Andreas and Kolberg, Hans-Christian
Geburtshilfe und Frauenheilkunde, ISSN 0016-5751, 11/2018, Volume 78, Issue 11, pp. 1110 - 1118
Abstract In primary early breast cancer, the aim of treatment planning is to obtain an increasingly better understanding of the disease. The identification of... 
GebFra Science | Prevention | Studies | Treatment | CDK4/6 | PD1/PDL1 | Risk | Breast cancer | Metastases | ADJUVANT CHEMOTHERAPY | OVARIAN SUPPRESSION | treatment | COMMON VARIANTS | WIDE ASSOCIATION ANALYSIS | SUSCEPTIBILITY LOCI | breast cancer | ESTROGEN-RECEPTOR | DISTANT RECURRENCE | OBSTETRICS & GYNECOLOGY | metastases | IDENTIFIES 2 | studies | CONFER SUSCEPTIBILITY | risk | PATIENT-LEVEL METAANALYSIS | prevention
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text In vivo blockade of the PD-1 pathway using soluble rPD-1-Fc enhances CD4+ and CD8+ T cell responses but has limited clinical benefit
by Amancha, Praveen K and Hong, Jung Joo and Rogers, Kenneth and Ansari, Aftab A and Villinger, Francois
Journal of immunology (Baltimore, Md. : 1950), ISSN 0022-1767, 12/2013, Volume 191, Issue 12
The PD-1/PD-Ligand pathway has been shown to limit cell mediated effector functions during chronic viral infections impeding clearance of pathogens. As a... 
PD1 blockade | SIVmac239 | soluble recombinant PD1 protein
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Two cases of granuloma annulare under anti-PD1 therapy
by Charollais, R and Aubin, F and Roche-Kubler, B and Puzenat, E
Annales de Dermatologie et de Venereologie, ISSN 0151-9638, 02/2018, Volume 145, Issue 2, pp. 116 - 119
Background: Granuloma annulare as a granulomatous cutaneous reaction may be drug-induced. Immune checkpoint inhibitors including programmed death-1 (PD-1)... 
Granuloma annulare | Melanoma | Anti-PD1
Journal Article
Details down arrow
7. Full Text The density of Tbet+ tumor-infiltrating T lymphocytes reflects an effective and druggable preexisting adaptive antitumor immune response in colorectal cancer, irrespective of the microsatellite status
by Ott, Eva and Bilonda, Linda and Dansette, Delphine and Deleine, Cécile and Duchalais, Emilie and Podevin, Juliette and Volteau, Christelle and Bennouna, Jaafar and Touchefeu, Yann and Fourquier, Pierre and El Alami Thomas, Wassila and Chetritt, Jérome and Bezieau, Stéphane and Denis, Marc and Toquet, Claire and Mosnier, Jean-François and Jarry, Anne and Bossard, Céline
OncoImmunology, ISSN 2162-4011, 04/2019, Volume 8, Issue 4, p. e1562834
Purpose: The recent success of anti-PD1 antibody in metastatic colorectal cancer (CRC) patients with microsatellite instability (MSI), known to be associated... 
microsatellite instability | explant culture | PD1/PDL1 | Colorectal cancer | Tbet | PD1 blockade | medullary carcinoma | IDO-1 | IFNγ response | Life Sciences | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Prise en charge des méningites aseptiques induites par les nouveaux traitements immunostimulants anticancéreux
by Mazoyer, Julie and Cuzzubbo, Stefania and Ursu, Renata and Belin, Catherine and Carpentier, Antoine
Revue Neurologique, ISSN 0035-3787, 04/2018, Volume 174, pp. S57 - S58
Anti-CTLA4 | Méningite | Anti-PD1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Myopathie inflammatoire oculo-bulbaire et respiratoire après traitement par pembrolizumab
by Chanson, Jean-Baptiste and Rego, Cécilia Alves Do and Lenormand, Cédric and Kremer, Laurent and Lannes, Béatrice and Echaniz-Laguna, Andoni
Revue Neurologique, ISSN 0035-3787, 04/2018, Volume 174, pp. S42 - S42
Traitement anticancéreux | Myopathie | Anti-PD1
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
by Wang, Chao and Sun, Wujin and Wright, Grace and Wang, Andrew Z and Gu, Zhen
Advanced Materials, ISSN 0935-9648, 10/2016, Volume 28, Issue 40, pp. 8912 - 8920
Inflammation‐triggered combination delivery of anti‐PD‐1 antibody and CpG oligodeoxynucleotides (CpG ODNs) has been demonstrated to prevent cancer relapse... 
anti‐PD1 | nanobiotechnology | CpG | drug delivery | cancer immunotherapy | anti-PD1 | EFFICIENT DELIVERY | SURGERY | PHYSICS, CONDENSED MATTER | PHYSICS, APPLIED | METASTASIS | MATERIALS SCIENCE, MULTIDISCIPLINARY | CHEMISTRY, PHYSICAL | NANOSCIENCE & NANOTECHNOLOGY | COMBINATION | CHEMISTRY, MULTIDISCIPLINARY | CELL LUNG-CANCER | BREAST-CANCER | THERAPY | RECURRENCE | TUMOR-GROWTH | IMMUNE-CHECKPOINT BLOCKADE | Neoplasms - therapy | Animals | Adjuvants, Immunologic | Immunotherapy | Antibodies | CpG Islands | Inflammation | Mice | Programmed Cell Death 1 Receptor - immunology | Drugs | Viral antibodies | Care and treatment | Drug delivery systems | Drug therapy | Cancer | Vehicles | Immune systems | Inflammatory response | Nanostructure | Survival | Controlled release
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Preclinical models of breast cancer: Two-way shuttles for immune checkpoint inhibitors from and to patient bedside
by Abdel-Aziz, Amal Kamal and Saadeldin, Mona Kamal and D'Amico, Paolo and Orecchioni, Stefania and Bertolini, Francesco and Curigliano, Giuseppe and Minucci, Saverio
European Journal of Cancer, ISSN 0959-8049, 11/2019, Volume 122, pp. 22 - 41
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Exacerbation of myasthenia gravis in a patient with melanoma treated with pembrolizumab
by Lau, K. H. Vincent and Kumar, Aditya and Yang, Irene Hwa and Nowak, Richard J
Muscle & Nerve, ISSN 0148-639X, 07/2016, Volume 54, Issue 1, pp. 157 - 161
Introduction : While anticancer immunotherapies have traditionally focused on activation of the immune system, there is recent interest in disinhibition of the... 
myasthenia gravis | pembrolizumab | melanoma | anti‐PD1 | immune checkpoint inhibitor | autoimmune adverse effect | anti-PD1 | PROGRAMMED DEATH-1 | SAFETY | AZATHIOPRINE | RECEPTOR | CANCER | NEUROSCIENCES | CLINICAL NEUROLOGY | METASTATIC MELANOMA | RESPONSES | MICE | PD-1 | EXPRESSION | Antibodies, Monoclonal, Humanized - adverse effects | Melanoma - complications | Myasthenia Gravis - complications | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Male | Aged | Myasthenia Gravis - chemically induced | Monoclonal antibodies | Care and treatment | Myasthenia gravis | Immunotherapy | Melanoma | Skin cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Incidence of Thyroid Function Test Abnormalities in Patients Receiving Immune‐Checkpoint Inhibitors for Cancer Treatment
by Patel, Nisha Subhash and Oury, Anais and Daniels, Gregory A and Bazhenova, Lyudmila and Patel, Sandip Pravin
The Oncologist, ISSN 1083-7159, 10/2018, Volume 23, Issue 10, pp. 1236 - 1241
This article reports the incidence of new‐onset thyroid function test abnormalities in patients undergoing treatment with ipilimumab, nivolumab, pembrolizumab,... 
Anti‐CTLA 4 | Pembrolizumab | Ipilimumab | Nivolumab | Anti‐PD1 | Thyroid | Anti-CTLA 4 | Anti-PD1 | UNTREATED MELANOMA | ONCOLOGY | HYPOPHYSITIS | ADVERSE EVENTS | Endocrinology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
by Chan, Matthew M. K and Kefford, Richard F and Carlino, Matteo and Clements, Arthur and Manolios, Nicholas
Journal of Immunotherapy, ISSN 1524-9557, 11/2014, Volume 38, Issue 1, pp. 37 - 39
We report the acute onset of polyarticular inflammatory arthritis in 2 patients receiving the immune check-point inhibitor, pembrolizumab (MK-3475), anti-PD1... 
Arthritis | Anti-PD1 antibody | PD1 | Immunotherapy | Melanoma | MEDICINE, RESEARCH & EXPERIMENTAL | arthritis | ONCOLOGY | PROGRAMMED DEATH-1 | SAFETY | immunotherapy | melanoma | IMMUNOLOGY | PD-1 | CANCER | anti-PD1 antibody | Antibodies, Monoclonal, Humanized - adverse effects | Arthritis - chemically induced | Antineoplastic Agents - adverse effects | Humans | Melanoma - drug therapy | Middle Aged | Female | Male | Aged | Tenosynovitis - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text PD1 signal transduction pathways in T cells
by Arasanz, Hugo and Gato-Cañas, Maria and Zuazo, Miren and Ibañez-Vea, Maria and Breckpot, Karine and Kochan, Grazyna and Escors, David
Oncotarget, ISSN 1949-2553, 02/2017, Volume 8, Issue 31, pp. 51936 - 51945
The use of immune checkpoint inhibitors for the treatment of cancer is revolutionizing oncology. Amongst these therapeutic agents, antibodies that block... 
PD-L1 | B7-H1 | PD1 | PDL1 | Cancer | ACTIVATION | PROTEIN | PROGRAMMED DEATH-1 | KINASE | CBL | CELL BIOLOGY | DOWN-MODULATION | PD-L1 CO-STIMULATION | cancer | NIVOLUMAB | BLOCKADE | ANTIGEN
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Pembrolizumab for Unresectable or Metastatic Melanoma in Patients Older than 85 Years of Age
by Chanal, Johan and Kramkimel, Nora and Ratour, Carole and Aractingi, Selim and Guégan, Sarah and Avril, Marie-Françoise
Dermatology, ISSN 1018-8665, 05/2019, Volume 235, Issue 3, pp. 219 - 224
Background: Programmed cell death protein-1 (PD-1) inhibitors (pembrolizumab and nivolumab) have been approved for the treatment of advanced melanoma. Over the... 
Skin Cancer – Research Article | Pembrolizumab | Octogenarians | Anti-PD1 | Melanoma | DERMATOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Arming an oncolytic herpes simplex virus type 1 with a single-chain fragment variable antibody against PD-1 for experimental glioblastoma therapy
by Passaro, Carmela and Alayo, Quazim and De Laura, Isabella and McNulty, John and Grauwet, Korneel and Ito, Hirotaka and Bhaskaran, Vivek and Mineo, Marco and Lawler, Sean E and Shah, Khalid and Speranza, Maria C and Goins, William and McLaughlin, Eric and Fernandez, Soledad and Reardon, David A and Freeman, Gordon J and Antonio Chiocca, E and Nakashima, Hiroshi
Clinical Cancer Research, ISSN 1078-0432, 01/2019, Volume 25, Issue 1, pp. 290 - 299
Purpose: Glioblastoma (GBM) is resistant to standard of care. Immune checkpoints inhibitors (such as anti-PD-1 mAbs) efficiently restore antitumor T-cell... 
TRIAL | MUTANT | HSV-1 | REPLICATION | G207 | ONCOLOGY | GLIOMA | CTLA-4 | PD1 | CHECKPOINT BLOCKADE
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Interferon-γ upregulates Δ42PD1 expression on human monocytes via the PI3K/AKT pathway
by Cheng, Lin and Tang, Xian and Xu, Liumei and Zhang, Lukun and Shi, Huichun and Peng, Qiaoli and Zhao, Fang and Zhou, Boping and Zhou, Yang and He, Yun and Wang, Hui and Gao, Zhiliang and Chen, Zhiwei
Immunobiology, ISSN 0171-2985, 05/2019, Volume 224, Issue 3, pp. 388 - 396
We recently identified a novel alternatively spliced isoform of human programmed cell death 1 (PD-1), named Δ42PD1, which contains a 42-base-pair in-frame... 
Δ42PD1 | JAK/STAT | Monocyte | Interferon-γ | PD-1 | PI3K/AKT
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. MBD4 inactivation induces a new mutator phenotype in cancers
by Rodrigues, Manuel and Mobuchon, Lenha and Houy, Alexandre and Derrien, Anne-Céline and Stern, Marc-Henri
Bulletin du Cancer, ISSN 0007-4551, 09/2018, Volume 105, Issue 9, pp. 736 - 737
MBD4 | Uveal melanoma | Immune checkpoints | Mutation | PD1
Journal Article
Details down arrow
20. Full Text GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF-κB-Dependent Mechanism
by Mondragón, Laura and Mhaidly, Rana and De Donatis, Gian Marco and Tosolini, Marie and Dao, Pascal and Martin, Anthony R and Pons, Caroline and Chiche, Johanna and Jacquin, Marie and Imbert, Véronique and Proïcs, Emma and Boyer, Laurent and Doye, Anne and Luciano, Frédéric and Neels, Jaap G and Coutant, Frédéric and Fabien, Nicole and Sormani, Laura and Rubio-Patiño, Camila and Bossowski, Jozef P and Muller, Florian and Marchetti, Sandrine and Villa, Elodie and Peyron, Jean-François and Gaulard, Philippe and Lemonnier, François and Asnafi, Vahid and Genestier, Laurent and Benhida, Rachid and Fournié, Jean-Jacques and Passeron, Thierry and Ricci, Jean-Ehrland and Verhoeyen, Els
Cancer Cell, ISSN 1535-6108, 09/2019, Volume 36, Issue 3, pp. 268 - 287.e10
GAPDH is emerging as a key player in T cell development and function. To investigate the role of GAPDH in T cells, we generated a transgenic mouse model... 
preclinical mouse model for AITL | glycolytic enzyme | NF-κB pathway | anti-PD1 immunotherapy | NF-κB-inducing kinase | angioimmunoblastic T cell lymphoma | PD1 | glyceraldehyde-3-phosphate-dehydrogenase | T follicular helper cells | germinal center B cells | LYSINE 27 | MELANOMA | ONCOLOGY | RHOA MUTATIONS | HISTONE H3 | GENE-EXPRESSION | DEATH | IMMUNE CHECKPOINT | MATURATION | CANCER | EZH2 | CELL BIOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.